Limulus Amebocyte Lysate

LAL (Limulus Amebocyte Lysate) is a sensitive biological reagent derived from horseshoe crab blood cells that laboratories use to detect bacterial endotoxins in drugs, peptides, and medical devices. This testing method identifies toxic bacterial fragments through an enzymatic reaction, with results typically reported in Endotoxin Units (EU/mg) on laboratory certificates.

Importance of LAL results for safety on a Certificate of Analysis

LAL testing is a critical safety metric on a Certificate of Analysis (COA), especially for injectable substances, because endotoxins can remain present even in sterile and chemically pure products. These heat-stable fragments of dead bacteria can trigger severe fever or septic shock, meaning a sample with 99% purity may still be unsafe if endotoxin levels are too high.

Interpretation limits and boundaries of LAL testing

• LAL is not a sterility test; it identifies toxic fragments of dead bacteria rather than checking for the presence of living microbes.
• The test provides no information regarding chemical purity, substance identity, or heavy metal content.
• While used to screen for pyrogens, LAL specifically detects bacterial endotoxins and not all types of fever-inducing substances.
• Modern laboratories are increasingly adopting synthetic recombinant Factor C (rFC) methods to reduce false positives and protect horseshoe crab populations.

Sources

1. Biochemical principle of Limulus test for detecting bacterial endotoxins
2. Evaluation of recombinant Factor C assay kits in comparison to compendial Limulus amebocyte lysate (LAL) assays for bacterial endotoxin testing | FDA
3. Bacterial Endotoxins/Pyrogens
4. Outstanding Contributions of LAL Technology to Pharmaceutical and Medical Science: Review of Methods, Progress, Challenges, and Future Perspectives in Early Detection and Management of Bacterial Infections and Invasive Fungal Diseases
5. Complete intra-laboratory validation of a LAL assay for bacterial endotoxin determination in EBV-specific cytotoxic T lymphocytes - PMC
6. A Study on the Application of Recombinant Factor C (rFC) Assay Using Biopharmaceuticals
7. Comparison of LAL and rFC Assays—Participation in a Proficiency Test Program between 2014 and 2019
8. [PDF] The Bacterial Endotoxins Specification – Points to Consider - FDA
9. Pyrogen and Endotoxins Testing: Questions and Answers
10. Figure 1, Key elements of the LAL enzymatic reaction and their specificity to endotoxin and β-(1,3)-D-glucans - National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols - NCBI Bookshelf
11. Assessment of Pyrogenic Response of Medical Devices and Biomaterials by the Monocyte Activation Test (MAT): A Systematic Review
12. General-EMEA/CHMP/BWP/452081/2007
13. [PDF] FDA PERSPECTIVE ON RECOMBINANT ENDOTOXIN DETECTION ...
14. Pyrogen and Endotoxins Testing: Questions and Answers - FDA
15. FDA Clarifies Current Thinking on Pyrogen and Endotoxins Testing
16. Understanding FDA Regulations on Peptides in 2026 | Informed Peptide
17. Pyrogen and Endotoxins Testing: Questions and Answers | FDA
18. Endotoxin Testing for Peptides | LAL & rFC Guide